Your session is about to expire
← Back to Search
Daratumumab and Hyaluronidase-fihj for Multiple Myeloma
Study Summary
This trial studies the side effects and possible benefits of adding panobinostat to a combination of other drugs for patients with relapsed or refractory multiple myeloma.
- Multiple Myeloma
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
What indications do Daratumumab and Hyaluronidase-fihj address?
"Daratumumab and Hyaluronidase-fihj is a mainstream treatment for ophthalmia, sympathetic. Additionally, it has been successful in addressing branch retinal vein occlusion, macular edema, as well as communicable diseases."
What other experiments have been conducted that involve Daratumumab and Hyaluronidase-fihj?
"This particular treatment, Daratumumab and Hyaluronidase-fihj, is currently under investigation in 686 clinical trials. 159 of these are Phase 3 studies located mainly in Hefei but also at 22940 locations around the world."
Is this experimental trial open to elderly participants?
"This trial seeks participants between the age of majority and 75 years old."
What are the major aims of this experiment?
"This 3 year trial will assess the recommended phase 2 dose for efficacy. Secondary assessment criteria include duration of overall response, time to response and progression-free survival which are all evaluated by employing Kaplan-Meier methods with 95% confidence intervals as well as log-rank test across patient subgroups."
Is it permissible for me to participate in this trial?
"The current medical trial seeks 27 individuals that have multiple myeloma, between 18 and 75 years of age. To qualify for the study, applicants must have had a prior course of therapy incorporating lenalidomide or cyclophosphamide, V or other PI with/without ASCT - however those who experienced progression within 120 days after their last treatment are ineligible. Additionally, participants should not be in receipt of any treatments two weeks before enrolling on this program."
Are researchers still enrolling participants in this experiment?
"Affirmative, the clinicaltrials.gov directory confirms that this medical trial is currently in search of participants. Initially posted on September 27th 2021 and recently updated on November 30th 2021, the study requires 27 individuals at one site to participate."
Has the FDA sanctioned utilization of Daratumumab and Hyaluronidase-fihj?
"The safety of Daratumumab and Hyaluronidase-fihj is estimated to be on the lower end, with a score of 1. This reflects its status as a Phase 1 trial which has little evidence showing efficacy or safety."
How many individuals are participating in this experiment?
"Affirmative. Clinicaltrials.gov indicates that this clinical trial is currently recruiting participants, with the initial posting of September 27th 2021 and a subsequent update on November 30th 2021. As such, 1 medical centre needs to enrol 27 patients in total."
Share this study with friends
Copy Link
Messenger